5 active not recruiting, 4 recruiting, 3 completed. 12 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Active not recruiting 5, Recruiting 4, Completed 3 |
| Phase 1 | 2 | Recruiting 2 |
Follow Dexamethasone oral: new trials by email Literature Review of Dexamethasone oral trials Research Report on Dexamethasone oral
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM Dexamethasone oral - Breast Neoplasms, Lung Neoplasms | Phase 2 | Recruiting | Brown University | 60 | 2025-10-22 | 2025-10-24 |
| Reducing Respiratory Symptoms of Pulmonary Irradiation in Interstitial Lung Disease N-Acetyl cysteine, Dexamethasone Oral, N-Acetyl cysteine Placebo - Lung Cancer, Interstitial Lung Disease | Phase 2 | Recruiting | David Palma | 98 | 2025-01-07 | 2026-08-26 |
| Subtyping Primary Aldosteronism With Para-chloro-2-[18F]Fluoroethyl-etomidate [18F]CETO tracer, Dexamethasone oral, Adrenal vein sampling - Primary Aldosteronism | Phase 1 / Phase 2 | Recruiting | University Medical Center Groningen | 12 | 2024-11-06 | 2025-01-27 |
| Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma Linperlisib, Camrelizumab, Pegaspargase - Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type, T-lymphoblastic Lymphoma | Phase 1 / Phase 2 | Recruiting | Beijing Tongren Hospital | 43 | 2024-04-14 | 2024-04-19 |
| Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis with Translocation (11;14) Venetoclax, Dexamethasone Oral - Light Chain (AL) Amyloidosis, CCND1 Translocation | Phase 2 | Active not recruiting | Peking Union Medical College Hospital | 36 | 2023-09-07 | 2025-01-22 |
| A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse." Ixazomib, Iberdomide, Dexamethasone Oral - Multiple Myeloma at First Relapse | Phase 2 | Active not recruiting | Nantes University Hospital | 75 | 2021-12-14 | 2026-06-15 |
| Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM Isatuximab-Irfc 20 MG/ML [Sarclisa], Lenalidomide, Dexamethasone Oral - Newly Diagnosed Multiple Myeloma | Phase 2 | Active not recruiting | Arbeitsgemeinschaft medikamentoese Tumortherapie | 198 | 2021-10-20 | 2025-04-10 |
| Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma Selinexor, Dexamethasone Oral, Daratumumab - Multiple Myeloma, Myeloma Multiple | Phase 2 | Active not recruiting | US Oncology Research | 73 | 2021-09-10 | 2025-01-16 |
| Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients Selinexor 20 MG Oral Tablet, Bortezomib Injection, Lenalidomide capsule - Multiple Myeloma | Phase 2 | Active not recruiting | Ida Bruun Kristensen | 50 | 2021-08-18 | 2026-10-16 |
| Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma Daratumumab Injection, Dexamethasone Oral, Lenalidomide Pill - Multiple Myeloma | Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 33 | 2019-11-22 | 2026-08-20 |
| Ketoconazole and Dexamethasone in Prostate Cancer Ketoconazole, Hydrocortisone, Dexamethasone - Prostate Cancer | Phase 2 | Completed | University of California, San Francisco | 32 | 2009-12-11 | 2020-06-29 |
| A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma elotuzumab, lenalidomide, dexamethasone oral - Hematologic Cancer | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 101 | 2008-08-01 | 2018-01-10 |
Multiple Myeloma (5) · Neoplasms, Plasma Cell (3) · Lung Neoplasms (2) · Amyloidosis (1) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Hematologic Neoplasms (1) · Hyperaldosteronism (1) · Lung Diseases, Interstitial (1) · Neoplasms (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1) · Prostatic Neoplasms (1) · Radiation Pneumonitis (1) · Triple Negative Breast Neoplasms (1)
AbbVie (prior sponsor, Abbott) (1) · Arbeitsgemeinschaft medikamentoese Tumortherapie (1) · Beijing Tongren Hospital (1) · Brown University (1) · David Palma (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Ida Bruun Kristensen (1) · Nantes University Hospital (1) · Peking Union Medical College Hospital (1) · US Oncology Research (1) · University Medical Center Groningen (1) · University of California, San Francisco (1)
United States (4) · China (2) · Austria (1) · Canada (1) · Denmark (1) · Estonia (1) · France (1) · Greece (1) · Netherlands (1) · Norway (1) · Serbia (1)
Cyrille Touzeau (1) · David Palma, MD (1) · Dr. M.N. Kerstens (1) · Hanne Norseth, MD (1) · Heinz Ludwig (1) · Houda Bahig, MD (1) · Ida B Kristensen, MB (1) · Liang Wang, M.D. (1) · Rachid C Baz, MD (1) · Robert M Rifkin, MD, FACP (1) · Stephanie Graff, MD (1) · Terence Friedlander, MD (1)
PMID 26686406, PMID 33859526, PMID 36074157, PMID 40983035
2023 (1)